1. Home
  2. GLRE vs CTKB Comparison

GLRE vs CTKB Comparison

Compare GLRE & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenlight Capital Re Ltd.

GLRE

Greenlight Capital Re Ltd.

N/A

Current Price

$15.02

Market Cap

501.7M

Sector

Finance

ML Signal

N/A

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

N/A

Current Price

$4.86

Market Cap

541.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GLRE
CTKB
Founded
2004
1990
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
501.7M
541.1M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
GLRE
CTKB
Price
$15.02
$4.86
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
$5.63
AVG Volume (30 Days)
104.3K
711.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
75.00
N/A
EPS
0.18
N/A
Revenue
$729,777,000.00
$193,015,000.00
Revenue This Year
N/A
$5.42
Revenue Next Year
N/A
$7.03
P/E Ratio
$83.17
N/A
Revenue Growth
4.85
17.67
52 Week Low
$11.57
$3.28
52 Week High
$19.39
$6.18

Technical Indicators

Market Signals
Indicator
GLRE
CTKB
Relative Strength Index (RSI) 39.02 57.21
Support Level $14.97 $4.17
Resistance Level $15.66 $5.24
Average True Range (ATR) 0.28 0.20
MACD 0.00 -0.00
Stochastic Oscillator 31.18 94.00

Price Performance

Historical Comparison
GLRE
CTKB

About GLRE Greenlight Capital Re Ltd.

Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

Share on Social Networks: